Cargando…

Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison

We tested the hypothesis that long-term treatment with pomaglumetad methionil would demonstrate significantly less weight gain than aripiprazole in patients with schizophrenia. In this 24-week, multicenter, randomized, double-blind, Phase 3 study, 678 schizophrenia patients were randomized to either...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adams, David H., Zhang, Lu, Millen, Brian A., Kinon, Bruce J., Gomez, Juan-Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977437/ https://www.ncbi.nlm.nih.gov/pubmed/24772351 http://dx.doi.org/10.1155/2014/758212

Ejemplares similares

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia
por: Adams, David H, et al.
Publicado: (2013)

A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia
por: Downing, AnnCatherine M, et al.
Publicado: (2014)

Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia
por: Nisenbaum, Laura K., et al.
Publicado: (2016)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
por: Evernden, Christopher, et al.
Publicado: (2021)

Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers
por: Kantrowitz, Joshua T., et al.
Publicado: (2020)

Aripiprazole for late-life schizophrenia
por: Rado, Jeffrey, et al.
Publicado: (2010)

Review of depot aripiprazole for schizophrenia
por: Motiwala, Farha Bilal, et al.
Publicado: (2013)

Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb, Nilufar, et al.
Publicado: (2012)

The Group of Treatment Resistant Schizophrenias. Heterogeneity in Treatment Resistant Schizophrenia (TRS)
por: Kinon, Bruce J.
Publicado: (2019)

Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial
por: Raghuthaman, G., et al.
Publicado: (2015)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study
por: Wani, Rayees Ahmad, et al.
Publicado: (2015)

Aripiprazole: the evidence of its therapeutic impact in schizophrenia
por: Winlow, William, et al.
Publicado: (2006)

Effect of Aripiprazole on Mismatch Negativity (MMN) in Schizophrenia
por: Zhou, Zhenhe, et al.
Publicado: (2013)

Aripiprazole-associated tic in a schizophrenia patient
por: Guo, Xieli, et al.
Publicado: (2015)

Effect of long-acting aripiprazole monohydrate on inpatient encounters: A retrospective mirror image study
por: Aguilar, Monica, et al.
Publicado: (2019)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]
Publicado: (2015)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
por: Hattori, Saki, et al.
Publicado: (2023)

Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study
por: Gu, Jiemei, et al.
Publicado: (2022)

Efficacy and tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Andrade, Chittaranjan
Publicado: (2004)

Efficacy and Tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Chavda, R.K., et al.
Publicado: (2004)

Retrospective Study of Japanese Patients with Schizophrenia Treated with Aripiprazole
por: Tanioka, Tetsuya, et al.
Publicado: (2012)

Treatment of refractory catatonic schizophrenia with low dose aripiprazole
por: Sasaki, Tsuyoshi, et al.
Publicado: (2012)

Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
por: Tien, Yun, et al.
Publicado: (2022)

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
por: Yingling, Jonathan M., et al.
Publicado: (2017)

A randomized, double-blind, placebo-controlled, multicenter study assessing the efficacy of magnesium oxide monohydrate in the treatment of nocturnal leg cramps
por: Barna, Olha, et al.
Publicado: (2021)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
por: James, Suneeta, et al.
Publicado: (2016)

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

A Case of Hypersexuality in a Patient Receiving Aripiprazole for Schizophrenia
por: Priya, Lakshmi, et al.
Publicado: (2021)

A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder
por: Mi, Weifeng, et al.
Publicado: (2023)

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder
por: Citrome, Leslie
Publicado: (2006)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Effect of Aripiprazole on Cognitive Function and Hyperprolactinemia in Patients with Schizophrenia Treated with Risperidone
por: Lee, Bong Ju, et al.
Publicado: (2013)

A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia
por: Pandey, Ravi S., et al.
Publicado: (2017)

Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia
por: Hori, Hikaru, et al.
Publicado: (2017)

Corrigendum to “Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia”
por: James, Suneeta, et al.
Publicado: (2019)

Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia
por: Cochran, Jeffrey M, et al.
Publicado: (2022)

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
por: Schöttle, Daniel, et al.
Publicado: (2018)

The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2017)

Probing Ly$\alpha$ absorbers with double lines of sight
por: Charlton, J C, et al.
Publicado: (1995)

Clinical experience with the new double aripiprazole depot regime in a psychiatric hospitalization unit
por: Moleón Ruiz, Á., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uqri681npt1lphhto6etltlug5